CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
Get Alerts CTIC Hot Sheet
Join SI Premium – FREE
SEATTLE, April 3, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 18th Annual Needham Healthcare Conference at 9:20 a.m. EDT at the Westin New York Grand Central.
Presentation details:
Event: | 18th Annual Needham Healthcare Conference |
Date: | Wednesday, Apr. 10 |
Time: | 9:20 a.m. EDT |
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma Corp.CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Argot Partners Maeve Conneighton/Maghan Meyers +1-212-600-1902[email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-18th-annual-needham-healthcare-conference-on-wednesday-apr-10-300823558.html
SOURCE CTI BioPharma Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acer Among Top 5% Scoring Companies in S&P Global Corporate Sustainability Assessment
- Finance in Motion and Napier AI partner on AML for secure impact investments
- AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Needham & Company, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!